ABB India: Could double...⚡ 🏭 📈 🔋 🚀
1. The Macro Setup: The Hunt Volatility Funnel
Look at the weekly chart.
NSE:ABB has spent over two years carving out a massive, highly symmetrical Hunt Volatility Funnel
@TheCryptoSniper
The Compression: After hitting macro resistance near 9,027 in mid-2024, the price underwent a deep, necessary cooling-off period.
The Squeeze: Throughout 2025 and early 2026, the price action compressed significantly, trapping liquidity within narrowing boundaries.
The Breakout Trigger: We are right at the edge of the knife. ABB is currently pressing hard against the upper bounds of the funnel at 7,021.
Volatility is coiled like a spring, and a clean weekly close outside this structure will signal a massive momentum expansion phase.
2. The Fundamental Core: Why ABB Deserves a Hyper-Premium
This isn't a speculative momentum play; it is a structural transformation story.
ABB India sits at the absolute epicentre of two of the most capital-intensive secular trends of this decade: the global AI data centre boom and India's massive power grid modernisation.
The AI Proxy Play (The Power Hunger)
The market is finally realising that AI is fundamentally an energy infrastructure story.
AI data centre's require 3x to 5x more power density than legacy facilities.
You cannot deploy advanced computing clusters without specialised, hyper-reliable electrification infrastructure.
ABB owns this bottleneck.
From advanced medium-voltage switchgear and smart distribution panels to digital energy management systems, ABB is the premier pick-and-shovel play.
They don't build the AI models—they build the physical nervous system that keeps them powered.
India's Power Grid Capital Expenditure Supercycle
Simultaneously, India is undergoing an unprecedented overhaul of its transmission and distribution infrastructure.
The integration of massive renewable energy capacity requires a digitized, robust, and highly automated grid to manage intermittent loads.
ABB’s electrification and automation divisions are capturing massive, high-margin order books as both public utilities and private industrial giants aggressively scale their capital expenditures.
3. Execution Coordinates & Multi-Tier Targets
The technical geometry on this chart provides clean, objective mathematical extensions to compound capital aggressively into outside space:
The Invalidation Line: The script has a line in the sand. A structural breakdown below the pattern fail zone at 6,652 invalidates the immediate expansion thesis.
Linear Target 1: 7,689
Linear Target 2: 8,619
Linear Target 3: 11,412
Logarithmic Target 3 (The Case for 2x): 13,687
When macro compression of this magnitude resolves to the upside, the extensions frequently overshoot standard linear targets.
Moving from the current compression block toward the Log target represents an absolute duplication of value—fully backed by structural corporate earnings power.
Let the crowd chase the late-stage hype.
We map the infrastructure bottlenecks early.
Onto the next block.
#ABBIndia #Infrastructure #CapExSupercycle #DataCenters #AIProxy #PriceAction #VolatilitySqueeze #ChartPatterns #NiftyInfra #TechnicalAnalysis #India IBM's revenue miss exposes AI-driven software spending shiftIBM | 1D Technical Analysis — Jul 17, 2026
IBM issued a Q2 pre-announcement warning, with preliminary revenue of $17.2B coming in 1% above last year but missing the $17.9B consensus. CEO Krishna explained that customers redirected quarterly capex toward servers, storage, and memory to secure constrained AI infrastructure, directly crowding out mainframe purchases. Krishna also cited Anthropic's Claude Mythos launch as a factor, noting it briefly paused enterprise contract signings as customers reassessed cybersecurity spending priorities. The confession has fueled broader market concern that enterprises are cutting software budgets to fund AI infrastructure, a read-across that rattled software sector sentiment broadly.
IBM has been in a volatile, multi-month period, with a sharp June spike to 332, followed by an equally sharp reversal that has now brought the price down to the 205 area, a decline of nearly 35% from the high in under two months. Price is currently trading around 220, with EMA21 (265.71) above EMA78 (262.83), though both EMAs are now trending lower following the recent breakdown, and the bullish cross that formed at early June is being rapidly unwound.
The daily chart shows a textbook distribution top, a spike to 330, immediate rejection, a lower high near 295, and then a cascading breakdown through 260, 233, and 205 in rapid succession. Today's 3.72% bounce from the 205 low is a technical relief move, but price remains well below both EMAs and all prior support levels that now act as overhead resistance. RSI at 32.90 is approaching oversold territory, providing the conditions for a short-term bounce but not yet confirming a structural bottom.
Key levels to watch:
Resistance: 233 / 260 / 262.83 (EMA78) / 265.71 (EMA21) / 295
Support: 205 (recent low) / 195 / 185 (structural floor)
Bear case: Failure to reclaim 233 on the current bounce and a rollover back toward 205 would suggest the low has not been established. A close below 205 opens the path toward 195 and the 185 structural floor, with the enterprise software spending narrative providing no near-term fundamental relief.
Bull case: A hold above 205 and a recovery through 233 would signal that the worst of the selling is absorbed. Reclaiming EMA78 at 262 and EMA21 at 265 would be the minimum requirement to suggest a structural recovery is underway, likely requiring a positive catalyst around the full Q2 earnings release.
Bias is bearish — the distribution-top structure, a breakdown through multiple support levels, and the fundamental admission that AI infrastructure spending is directly cannibalizing IBM's core software business create a difficult setup. The 205 level is the line in the sand. Without a hold here, further downside toward 195–185 remains the path of least resistance.
Long
Long
Short
Short
ORCL - From Erections Come CorrectionsORCL is a textbook example of a setup I call: “From Erections Come Corrections.”
1. It also shows why log charts lie to you on the way down.
When you’re evaluating downside risk, remember: every stock is always 100% away from zero.
A linear chart makes the real danger obvious. I don’t even need to measure this one — the drop is roughly 50% staring you in the face.
2. Look at the speed of that drop.
If you’re one of those heroes trying to squeeze an extra 3% at the top and end up wearing a -50% drawdown because you had no exit plan… that’s not bad luck — that’s greed and negligence teaming up to hand you a bag of sh*t.
3. But if you actually respected risk, took profits, and GTFO/STFO with cash in hand?
Now you get to walk back in as a well-refined gentleman or lady, gracefully to start building a position at at a “500% discount,” as Trump would say.
4. Notice anything magical on my chart?0
No algos. No secret indicators. No fairy-tale narratives. Not even candlesticks. Just plain vanilla price action.
That’s proper charting. Keep it simple.
You chose to play this game, so at least play it right.
Lastly, if the market tanks here, ORCL will just keep tanking as well. BUT! you will be getting in with a 50% discount already. That, my friends, is the difference.
THANK YOU for getting me to 5,000 followers! 🙏🔥
Let’s keep climbing.
If you enjoy the work:
👉 Drop a solid comment
Let’s push it to 6,000 and keep building a community grounded in truth, not hype.
Long 
Long
Long
TITANTitan Company Ltd. (CMP ₹4,625.00, NSE: TITAN)
The SmartWay Research Desk | 17 July 2026
A Bengaluru‑based consumer goods company, incorporated in 1984. Titan operates across watches, jewellery, eyewear, and lifestyle accessories, with flagship brands like Tanishq, Fastrack, Sonata, Titan Eye+, CaratLane, and Skinn perfumes.
Promoter Holding (Mar 2026): Tata Group — 52.90% stake (no pledges)
FY22–FY26 Snapshot
Revenue Growth: FY26 revenue ₹46,842 Cr vs ₹41,212 Cr in FY25 (+13.6% YoY). → Good
Net Profit: FY26 PAT ₹4,812 Cr vs ₹4,212 Cr in FY25 (+14.2% YoY). → Good
Operating Margin: FY26 EBITDA ₹7,212 Cr, margin 15.4% vs 14.8% last year (+60 bps). → Good
Equity Capital: Stable, face value ₹1. → Good
Dividend Policy: Dividend ₹12.00/share declared for FY26. → Good
Asset Building: Investments in digital jewellery retail, omni‑channel eyewear, and CaratLane expansion. → Good
Sales: Strong demand from Tanishq jewellery and Fastrack watches. → Good
Expense: Gold price volatility impacts margins. → Neutral/Good
EPS: FY26 EPS ₹54.25 vs ₹47.50 last year (+14.2%). → Good
Institutional Interest & Ownership Trends (Mar 2026)
Promoter Holding: 52.90% (no pledges)
FII Holding: 18.12%
DII Holding: 20.34%
Retail & Others: 8.64%
Strategic Moves & Innovations
Expansion in CaratLane and digital jewellery retail.
Focus on premium watch and smart wearable segment.
Partnerships with global eyewear brands for Titan Eye+.
Diversification into perfumes, accessories, and lifestyle products.
Cash Flow & Balance Sheet Strength
Market cap ~₹4,10,000 Cr.
Debt‑to‑equity ratio ~0.18 (low leverage).
Book value per share ₹412.00; P/B ~11.2.
EPS (TTM) ₹54.25; P/E ~85.3.
Risk Factors
High P/E ratio ~85.3, indicating premium valuations.
Dependence on gold price cycles and consumer discretionary demand.
Exposure to competition in jewellery and lifestyle retail.
Competition from Kalyan Jewellers, Malabar Gold, and HUL in lifestyle segments.
Investor Takeaway
Titan has delivered robust FY26 performance, supported by jewellery demand, watch segment revival, and lifestyle diversification. With strong promoter backing, dividend payouts, and leadership in branded jewellery, Titan remains a premium FMCG‑retail play. At CMP ₹4,625.00, valuations are very expensive (P/E ~85.3, P/B ~11.2), reflecting strong growth expectations but also sectoral risks. 
Long
Long
Long
AAPL Final Leg of June 15 Impulse Rally Before PullbackApple (AAPL) continues to extend its advance, breaking to new all‑time highs in a powerful impulsive structure. The short‑term cycle from the June 26, 2026 low remains in progress and is unfolding as a clear five‑wave rally. From that low, wave 1 ended at $288.37, followed by a corrective pullback in wave 2 that completed at $279.85. The stock then resumed higher in wave 3, reaching $315.93, before a modest retracement in wave 4 concluded at $306.95, as reflected in the thirty‑minute chart.
Wave 5 is now in progress, developing with internal subdivision into another five waves. From the wave 4 low, wave ((i)) advanced to $323.45, while the subsequent pullback in wave ((ii)) ended at $311.91. The stock has since resumed higher within wave ((iii)), reinforcing the bullish sequence. As long as the pivot at $306.95 remains intact, the near‑term expectation is for dips to continue finding support. These corrective phases are likely to unfold in 3, 7, or 11 swings, providing opportunities for further upside before the five‑wave rally from the June 26 low reaches completion.
Once the current impulsive cycle concludes, attention will shift toward a larger corrective phase. The anticipated three‑wave pullback should serve to correct the advance from the June 26 low, offering a broader reset in the structure. This outlook highlights both the strength of the ongoing rally and the importance of monitoring key pivots to confirm continuation before the larger correction unfolds. 
Long
Long
Long
Short
Short
RAYA - EGX : Technical Analysis / Daily and Weekly time-framesEGX:RAYA
1. Trend & Macro Structure (Weekly Timeframe)
Primary Trend: Strongly Bullish.
Key Structural Breakthrough: The stock completed a major macro breakout above its long-term ascending resistance line (Zone 5.75 – 6.00 EGP), accelerating into an explosive multi-month rally.
Current Phase: Following a peak at 8.68 EGP, the price is currently undergoing a classic breakout retest and profit-taking consolidation.
Weekly Indicators:
- MACD (12, 26, 9): Bullish alignment above the zero line (0.935 / 0.898), confirming strong underlying structural momentum.
- RSI (14): 72.71 — Maintaining position in elevated bullish expansion territory, though showing minor cooling off from peak overbought extremes.
2. Short-Term Price Action (Daily Timeframe)
Pattern Realization: RAYA broke out of a multi-week symmetrical triangle / pennant continuation structure near 7.55 – 7.60 EGP, pushing rapidly to test 8.68 EGP.
Current Dynamics: The recent pullbacks over the last few sessions towards 7.89 EGP represent a normal health-check retest of the breakout base.
Daily Indicators:
- RSI (14): Re-entered neutral ground at 54.80, resolving short-term overbought conditions without breaking market structure.
- MACD: Lines are flattening around 0.24 with histogram momentum ticking neutral (-0.000), indicating short-term momentum deceleration prior to direction confirmation.
3. Key Technical Levels
Technical Level | Price (EGP) | Significance
• Major Target / Resistance 2 | 9.50 – 9.80 Triangle breakout pattern measured target.
• Immediate Resistance 1 | 8.68 Recent swing high / local supply ceiling.
• Short-Term Pivot / Rebound Level 8.10 – 8.20 Intraday hurdle to confirm bull resumption.
• Current Close | 7.89 Neutral consolidation zone.
• Immediate Support (Breakout Zone) 7.40 – 7.60 Top boundary of broken triangle & primary pull-back buy zone.
• Primary Structural Support / Stop | 7.00 – 7.15 Major trendline support & structural invalidation level.
4. Scenario Analysis & Next Sessions Expectation
Primary Scenario : Bullish Retest & Rebound (High Probability)
Expectation : Price stabilizes in the 7.50 – 7.80 EGP region. As long as 7.40 EGP holds on a daily closing basis, the consolidation remains structural health.
Trigger : A daily move back above 8.10 EGP on expanding volume will signal the end of the corrective phase, reopening the pathway toward 8.68 EGP, with an extended target reaching 9.50+ EGP.
Secondary Scenario : Deeper Retracement (Low-to-Medium Probability)
Expectation: If selling pressure breaches 7.40 EGP, a deeper retest toward the lower bound of the underlying trendline at 7.00 – 7.15 EGP will occur.
Risk Management : A daily close below 7.00 EGP invalidates the short-term bullish momentum, requiring a transition to a defensive stance. 
Long
Long
Long
Q1 2026 13F: The 10 Biotech Names 20 Funds Actually Bought▪️ Q1 2026 13F — INSTITUTIONAL CONVICTION SNAPSHOT
▪️ 20 specialist biotech funds filed Q1 2026: 73 brand-new positions, 201 positions increased, and — notably — zero complete exits. Nobody is walking away from anything. Capital is being added, not rotated out.
▪️ Filings run on a 45-day delay, so this is a map of where conviction was built during the quarter, not a live tape. The signal is convergence: when independent specialist funds land on the same name in the same window, that is the tell worth trading around.
▪️ Primary read is risk-on and accumulative. New-money convergence is clustering in early-stage oncology and cell therapy; add-money is concentrating in mid/late-stage names that already have institutional ownership — funds doubling down on work already done.
▪️ TOP 10 CONVICTION IDEAS
▪️ 1 — DFTX (Definium Therapeutics) · 7 funds · new · $335M
Highest convergence on the entire filing. Seven specialists initiating cold in one quarter is the rarest signal in this dataset. Driehaus, Avoro, Deep Track +4.
▪️ 2 — INSM (Insmed) · 4 funds adding · $2.1B
Largest capital block on the sheet. Baker Bros, RTW and Eventide adding to a $2B position is scale conviction, not a starter bet.
▪️ 3 — PRAX (Praxis Precision Medicines) · 5 funds adding · $1.9B
Five funds adding into a near-$2B book. Best blend of breadth and size — the strongest conviction-plus-scale name here.
▪️ 4 — DMRA (Damora Therapeutics) · 5 funds · new · $282M
Second-highest new-position convergence. Avoro, RA Capital, Commodore +2 all stepping in fresh at meaningful size.
▪️ 5 — RVMD (Revolution Medicines) · 4 funds adding · $1.2B
Billion-dollar position getting bigger. Baker Bros, Avoro and Perceptive adding together is a heavyweight cluster.
▪️ 6 — CNTA (Centessa Pharmaceuticals) · 5 funds adding · $668M
Five-fund add at mid-cap size. EcoR1, Perceptive and Deep Track leaning in on an existing book.
▪️ 7 — PCVX (Vaxcyte) · 4 funds adding · $1.0B
Billion-dollar position, four funds adding. Institutional core holding being reinforced, not trimmed.
▪️ 8 — TNGX (Tango Therapeutics) · 5 funds adding · $469M
Broadest add outside the mega-positions. RTW, Deerfield and Deep Track stacking on the same name.
▪️ 9 — IRTC (iRhythm Holdings) · 4 funds · new · $330M
Largest new-position dollar value relative to fund count — the medtech outlier in an otherwise therapeutics-heavy list. High conviction per fund.
▪️ 10 — AKTS (Aktis Oncology) · 5 funds · new · $169M
Five-fund cold start. EcoR1, RTW and RA Capital converging on radiopharma exposure at the same time.
▪️ WHAT DIDN'T MAKE THE CUT
CMPS, CGON, XENE, IRON, CRVS, IPSC, STRO, AGMB, ZURA, EIKN — real activity, but either thin fund counts, sub-$100M size, or both. Not enough weight behind them to trade off. Skipped.
▪️ THE STRUCTURAL TELL
Zero exits across 20 funds is the number to sit with. Specialists are not de-risking. Every dollar of movement this quarter was directional accumulation — new convergence at the small-cap end (DFTX, DMRA, AKTS), reinforcement at the large end (INSM, PRAX, RVMD, PCVX). That is a barbell, and it usually precedes a catalyst-heavy stretch.
▪️ ProjectSyndicate Levels Desk — Overview of key S/R zones for NQ, ES, GC & JPN225 traders every week. Subscribe to stay up to date with the latest levels. 
Long
